[logo] HealthTree Foundation
more_vert
close
person Sign In / Create Account

Dr. Robert Z. Orlowski discusses immunotherapies, early smoldering myeloma treatment and clinical trials

Dr. Robert Z. Orlowski discusses immunotherapies, early smoldering myeloma treatment and clinical trials image

Dr. Robert Z. Orlowski discusses immunotherapies, early smoldering myeloma treatment and clinical trials

Podcast
event Jul 05, 2013 / 10:00AM MDT
link icon facebook logo X logo linkedin logo reddit logo email icon

Event Description

Dr. Orlowski discusses his research and how faster progress could be made towards a cure if more patients participated in clinical trials. The interview covers four of the latest areas in myeloma research that Dr. Orlowski is pursuingNew treatment approaches where smoldering myeloma is treated earlier, Antibody treatments called PD-1 using a class of drugs already approved for melanoma, Two new immunotherapy approaches where the patient's immune system attacks the myeloma cells including a vaccine approach pre-transplant and also a way of purifying the gene that produces the abnormal protein that is then re-injected to try to stimulate an immune response. Dr. Orlowski also discussed a new class of drugs that prevent myeloma cells from making the protein Stat 3. 

Schedule & Agenda

Event panelist Jenny Ahlstrom & Dr. Robert Z. Orlowski
12:00 PM
Discussion
Jenny Ahlstrom & Dr. Robert Z. Orlowski
Dr. Orlowski discusses his research and how faster progress could be made towards a cure if more patients participated in clinical trials.

Speakers & Moderators

The panelist Jennifer Ahlstrom
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.

Read Bio
The panelist Robert Orlowski, MD, PhD
Robert Orlowski, MD, PhD

Robert Z. Orlowski, M.D., Ph.D., is Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics, where he is board-certified in medical oncology. Dr. Orlowski earned his doctoral degree in molecular biophysics and biochemistry from Yale University and his medical degree from the Yale University School of Medicine. He completed his internship and residency in Internal Medicine at Barnes Hospital at the Washington University in St. Louis School of Medicine. After his fellowships in Hematology and Medical Oncology at John Hopkins Sidney Kimmel Comprehensive Cancer Center, he joined the faculty at University of North Carolina in Chapel Hill. Following that, Dr. Orlowski accepted a position at The University of Texas MD Anderson Cancer Center in 2007 to lead the Myeloma Section in the Department of Lymphoma/Myeloma. His research interests include pathobiology of, novel therapeutic targets and mechanisms of drug resistance in myeloma which are documented in hundreds of scientific articles, book chapters, and presentations at conferences. Dr. Orlowski is an investigator on numerous clinical trials, and appointed Myeloma Committee Chair for SWOG.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

1-800-709-1113

email

Support@healthtree.org

Thanks to our sponsors:
Johnson and Johnson logo
Sanofi logo
Pfizer logo
GSK logo
Regeneron logo
All HealthTree resources available anywhere, anytime
Download our App
Download iOS App Download Android App
iphone app mockup
newsletter icon

Get the Latest Acute Myeloid Leukemia Updates, Delivered to You.

By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.